Ongoing trials involving angiotensin-converting enzyme inhibitors

Sunil Nadar, Gregory Y H Lip

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Angiotensin-converting enzyme inhibitors (ACEIs) are an important class of drugs in cardiovascular disease. As their name suggests, they act by blocking angiotensin converting enzyme, thereby limiting the production of angiotensin II, the most active component of the renin-angiotensin-aldosterone system. This system plays an important role in maintenance of blood pressure and electrolyte and fluid balance. Therefore, by blocking this system, the ACEIs have wide ranging effects. Recent trials have reaffirmed their place in the management of hypertension, congestive cardiac failure, in the prevention of renal complications in diabetes and the prevention of strokes in 'at risk' patients. There are still many ongoing trials using the ACEIs. These trials are mainly aimed at comparing their efficacy with 'older' drugs (such as β-blockers) and 'newer' drugs such as the angiotensin receptor blockers and calcium antagonists in different indications, such as heart failure and diabetic nephropathy. The impact of these drugs on the prevention of macro- and micro vascular complications in diabetes is also being investigated. The results of all these trials, when available, are expected to reaffirm the important role of this class of drugs in our modern day medical armamentarium. In this review, the ongoing clinical trials involving ACEIs, the rationale behind these trials and what impact they hope to have on our current understanding of the role of this important class of drug in medical practice, will be discussed.

Original languageEnglish
Pages (from-to)1633-1643
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume11
Issue number11
DOIs
Publication statusPublished - Nov 1 2002

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Pharmaceutical Preparations
Water-Electrolyte Balance
Diabetes Complications
Hope
Heart Failure
Angiotensin Receptor Antagonists
Diabetic Nephropathies
Peptidyl-Dipeptidase A
Renin-Angiotensin System
Angiotensin II
Names
Blood Vessels
Cardiovascular Diseases
Stroke
Maintenance
Clinical Trials
Blood Pressure
Hypertension
Calcium

Keywords

  • Angiotensin-converting enzyme inhibitors
  • Clinical trials
  • Congestive cardiac failure
  • Hypertension

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ongoing trials involving angiotensin-converting enzyme inhibitors. / Nadar, Sunil; Lip, Gregory Y H.

In: Expert Opinion on Investigational Drugs, Vol. 11, No. 11, 01.11.2002, p. 1633-1643.

Research output: Contribution to journalReview article

@article{4476bc80b8544f65a118378d683a04e2,
title = "Ongoing trials involving angiotensin-converting enzyme inhibitors",
abstract = "Angiotensin-converting enzyme inhibitors (ACEIs) are an important class of drugs in cardiovascular disease. As their name suggests, they act by blocking angiotensin converting enzyme, thereby limiting the production of angiotensin II, the most active component of the renin-angiotensin-aldosterone system. This system plays an important role in maintenance of blood pressure and electrolyte and fluid balance. Therefore, by blocking this system, the ACEIs have wide ranging effects. Recent trials have reaffirmed their place in the management of hypertension, congestive cardiac failure, in the prevention of renal complications in diabetes and the prevention of strokes in 'at risk' patients. There are still many ongoing trials using the ACEIs. These trials are mainly aimed at comparing their efficacy with 'older' drugs (such as β-blockers) and 'newer' drugs such as the angiotensin receptor blockers and calcium antagonists in different indications, such as heart failure and diabetic nephropathy. The impact of these drugs on the prevention of macro- and micro vascular complications in diabetes is also being investigated. The results of all these trials, when available, are expected to reaffirm the important role of this class of drugs in our modern day medical armamentarium. In this review, the ongoing clinical trials involving ACEIs, the rationale behind these trials and what impact they hope to have on our current understanding of the role of this important class of drug in medical practice, will be discussed.",
keywords = "Angiotensin-converting enzyme inhibitors, Clinical trials, Congestive cardiac failure, Hypertension",
author = "Sunil Nadar and Lip, {Gregory Y H}",
year = "2002",
month = "11",
day = "1",
doi = "10.1517/13543784.11.11.1633",
language = "English",
volume = "11",
pages = "1633--1643",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Ongoing trials involving angiotensin-converting enzyme inhibitors

AU - Nadar, Sunil

AU - Lip, Gregory Y H

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Angiotensin-converting enzyme inhibitors (ACEIs) are an important class of drugs in cardiovascular disease. As their name suggests, they act by blocking angiotensin converting enzyme, thereby limiting the production of angiotensin II, the most active component of the renin-angiotensin-aldosterone system. This system plays an important role in maintenance of blood pressure and electrolyte and fluid balance. Therefore, by blocking this system, the ACEIs have wide ranging effects. Recent trials have reaffirmed their place in the management of hypertension, congestive cardiac failure, in the prevention of renal complications in diabetes and the prevention of strokes in 'at risk' patients. There are still many ongoing trials using the ACEIs. These trials are mainly aimed at comparing their efficacy with 'older' drugs (such as β-blockers) and 'newer' drugs such as the angiotensin receptor blockers and calcium antagonists in different indications, such as heart failure and diabetic nephropathy. The impact of these drugs on the prevention of macro- and micro vascular complications in diabetes is also being investigated. The results of all these trials, when available, are expected to reaffirm the important role of this class of drugs in our modern day medical armamentarium. In this review, the ongoing clinical trials involving ACEIs, the rationale behind these trials and what impact they hope to have on our current understanding of the role of this important class of drug in medical practice, will be discussed.

AB - Angiotensin-converting enzyme inhibitors (ACEIs) are an important class of drugs in cardiovascular disease. As their name suggests, they act by blocking angiotensin converting enzyme, thereby limiting the production of angiotensin II, the most active component of the renin-angiotensin-aldosterone system. This system plays an important role in maintenance of blood pressure and electrolyte and fluid balance. Therefore, by blocking this system, the ACEIs have wide ranging effects. Recent trials have reaffirmed their place in the management of hypertension, congestive cardiac failure, in the prevention of renal complications in diabetes and the prevention of strokes in 'at risk' patients. There are still many ongoing trials using the ACEIs. These trials are mainly aimed at comparing their efficacy with 'older' drugs (such as β-blockers) and 'newer' drugs such as the angiotensin receptor blockers and calcium antagonists in different indications, such as heart failure and diabetic nephropathy. The impact of these drugs on the prevention of macro- and micro vascular complications in diabetes is also being investigated. The results of all these trials, when available, are expected to reaffirm the important role of this class of drugs in our modern day medical armamentarium. In this review, the ongoing clinical trials involving ACEIs, the rationale behind these trials and what impact they hope to have on our current understanding of the role of this important class of drug in medical practice, will be discussed.

KW - Angiotensin-converting enzyme inhibitors

KW - Clinical trials

KW - Congestive cardiac failure

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=0036848025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036848025&partnerID=8YFLogxK

U2 - 10.1517/13543784.11.11.1633

DO - 10.1517/13543784.11.11.1633

M3 - Review article

VL - 11

SP - 1633

EP - 1643

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 11

ER -